October 31, 2022 12:57 PM EDT

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others

Nicole DeFeudis

Editor

Several drugmakers, including Sandoz and Teva, are banking on swift approvals for their generic versions of the endometriosis drug Orilissa — but not if AbbVie can …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Ab­b­Vie puts up fight against Orilis­sa gener­ics from San­doz, Te­va and oth­ers

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AbbVie puts up fight against Orilissa generics from Sandoz, Teva and others